Patent: 6,589,941
✉ Email this page to a colleague
Summary for Patent: 6,589,941
| Title: | Utilization of 5\' substituted nucleosides for resistance formation in cytoclastic treatment, and drug containing these nucleosides, polymers, methods of use and compositions |
| Abstract: | The invention relates to a method of producing a composition and to a composition for preventing or reducing formation of resistance in cytostatic treatment comprising combining BVDU, a salt thereof or BVDU in protected form or in prodrug form with at least one cytostatic agent in order to prevent or reduce the formation of resistance during cytostatic treatment. The present invention is also directed to a method of reducing resistance in cytostatic treatment comprising delivering therapeutically-effective amount of at least one cytostatic agent and a therapeutically effective amount of BVDU, a salt thereof, or BVDU in protected form or in prodrug form. |
| Inventor(s): | Fahrig; Rudolf (Hannover, DE), Steinkamp-Zucht; Angela (Hannover, DE) |
| Assignee: | Resprotect GmbH (Dresden, DE) |
| Application Number: | 09/520,901 |
| Patent Claims: | see list of patent claims |
Details for Patent 6,589,941
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2015-02-01 |
| Merck Teknika Llc | TICE BCG | bcg live | For Injection | 102821 | 06/21/1989 | ⤷ Try a Trial | 2015-02-01 |
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2015-02-01 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
